ОбзорГрафикНовостиTraderScreen

HSBC Knock-Out MorphoSys AG/  DE000HS4KDD9  /

Frankfurt Zert./HSBC
15.10.2024  14:00:49 Изменение-0.010 Бид15.10.2024 Предложение15.10.2024 Базовый актив Цена исполнения Дата истечения Тип опциона
27.770EUR -0.04% -
Величина цены спроса: -		 -
Величина цены предложения: -		 MOR 40.7192 - 31.12.2078 Call
GlobeNewswire 16.07 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of M...
TeleTrader 11.04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 12.03 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 05.02 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 11.08.2021 Royalty Pharma Reports Second Quarter 2021 Results
GlobeNewswire 03.06.2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 02.06.2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 27.04.2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 28.10.2019 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 23.04.2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 23.04.2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 31.01.2019 Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
GlobeNewswire 13.09.2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 13.09.2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 12.09.2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 12.09.2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 19.07.2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 19.07.2018 Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atop...
GlobeNewswire 19.07.2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 01.05.2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 01.05.2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 19.04.2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 17.02.2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 17.02.2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 27.09.2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...